RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
0.5468
+0.0078 (1.45%)
Oct 12, 2026, 1:13 PM EDT - Market open
RedHill Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 0.29 | - | - | 61.8 | 85.76 | |
Revenue Growth | - | - | - | - | -27.94% | 33.25% |
Cost of Revenue | - | - | - | - | 33.34 | 49.41 |
Gross Profit | - | 0.29 | - | - | 28.46 | 36.35 |
Selling, General & Admin | 5.97 | 6.17 | 4.89 | 6.02 | 64.03 | 87.99 |
Research & Development | 2.02 | 2.02 | 1.59 | 3.53 | 7.28 | 29.5 |
Operating Expenses | 7.99 | 8.2 | 6.48 | 9.55 | 71.31 | 117.49 |
Operating Income | -7.99 | -7.91 | -6.48 | -9.55 | -42.84 | -81.14 |
Interest Expense | -0.3 | -0.02 | -0.04 | -0.06 | -41.33 | -16.57 |
Interest & Investment Income | 0.01 | 0.02 | 0.08 | 0.09 | 0.14 | 0.05 |
Earnings From Equity Investments | -0.69 | -0.03 | - | - | - | - |
Currency Exchange Gain (Loss) | -0.09 | -0.09 | 0.03 | -0.12 | -0.04 | -0.03 |
Other Non Operating Income (Expenses) | -1.8 | -0.06 | 6.77 | -7.4 | 12.41 | -0.07 |
EBT Excluding Unusual Items | -10.87 | -8.08 | 0.36 | -17.04 | -71.67 | -97.74 |
Other Unusual Items | - | - | - | -1.46 | - | - |
Pretax Income | -10.87 | -8.08 | 0.36 | -18.5 | -71.67 | -97.74 |
Earnings From Continuing Operations | -10.87 | -8.08 | 0.36 | -18.5 | -71.67 | -97.74 |
Earnings From Discontinued Operations | 8.47 | 7.65 | -8.63 | 42.41 | - | - |
Net Income | -2.4 | -0.43 | -8.27 | 23.92 | -71.67 | -97.74 |
Net Income to Common | -2.4 | -0.43 | -8.27 | 23.92 | -71.67 | -97.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | 3 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | - | 3 | 1 | 0 | 0 | 0 |
Shares Change | - | 156.37% | 375.56% | 320.45% | 32.46% | 27.72% |
EPS (Basic) | - | -0.14 | -6.71 | 92.30 | -1162.89 | -2100.80 |
EPS (Diluted) | - | -0.14 | -6.71 | 92.30 | -1162.89 | -2100.80 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -7.78 | -7.2 | -8.94 | -16.83 | -29.38 | -65.16 |
Free Cash Flow Per Share | - | -2.28 | -7.26 | -64.96 | -476.76 | -1400.52 |
Gross Margin | - | 100.00% | - | - | 46.06% | 42.39% |
Operating Margin | - | -2765.38% | - | - | -69.33% | -94.61% |
Profit Margin | - | -150.00% | - | - | -115.97% | -113.98% |
Free Cash Flow Margin | - | -2516.08% | - | - | -47.55% | -75.98% |
EBITDA | -7.9 | -7.79 | -6.38 | -7.56 | -34.69 | -62.99 |
EBITDA Margin | - | - | - | - | -56.13% | -73.45% |
D&A For EBITDA | 0.09 | 0.12 | 0.1 | 1.99 | 8.15 | 18.15 |
EBIT | -7.99 | -7.91 | -6.48 | -9.55 | -42.84 | -81.14 |
EBIT Margin | - | - | - | - | -69.33% | -94.61% |